IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4507
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$89M
Brian C. Thomas
We are a precision genetic medicines company committed to developing curative therapeutics for patients using our proprietary, comprehensive metagenomics-derived genome editing toolbox. Our principal executive offices are located 5959 Horton Street, 7th Floor, Emeryville, California.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MGX Metagenomi, Inc. | 30 | 36 | 9 | 23 | - | - | -47.1% | -33.9% | 100.0% | -344.7% | -309.8% | -56.7% | 0.0% | 39.0x | $89M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Metagenomi, Inc. (MGX) receives a "Avoid" rating with a composite score of 30.3/100. It ranks #4507 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MGX.
View All RatingsROE proxy -47.1% (sector -1.9%)
GM 100% vs sector 44%, OM -345% vs sector 3%
Capital turnover N/A, R&D intensity 342.4%
Rev growth -57%, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Metagenomi, Inc. (MGX) as Avoid with a composite score of 30.3/100 at a current price of $1.44. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Metagenomi, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.3/100 places it at rank #4507 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
Metagenomi, Inc. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Metagenomi, Inc. with an Avoid rating, assigning a composite score of 30.3/100 and 1 out of 5 stars. Ranked #4507 of 7,333 stocks, MGX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
MGX's quality score of 36/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -47.1% (sector avg: -1.9%), gross margins of 100.0% (sector avg: 44.1%), net margins of -309.8% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
MGX registers a value score of just 9/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.31x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 41/100, MGX exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of -56.7% vs. a sector average of 6.7% and a return on assets of -33.9% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
Metagenomi, Inc. is experiencing notably weak momentum with a score of just 23/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -56.7% year-over-year, while a beta of 1.07 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
MGX's stability score of 44/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.07 and a debt-to-equity ratio of 39.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Metagenomi, Inc.'s short interest score of 23/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 39.00x), micro-cap liquidity risk. At $89M (micro-cap), MGX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Metagenomi, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4507 of 7,333 overall (39th percentile). Key comparisons include ROE of -47.1% trailing the -1.9% sector median and operating margins of -344.7% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MGX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (9) would have the largest impact on the composite score.
ROE 2381% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 127% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 13833% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Metagenomi, Inc. (NASDAQ:MGX) has received a consensus "Moderate Buy" rating from five brokerages, with an average one-year target price of $10.00. The biotechnology company, specializing in genomics and CRISPR-based gene editing, reported a recent quarter that surpassed EPS and revenue estimates despite showing deep losses and trading at a low market capitalization. Institutional investors have adjusted their positions in MGX, with some significantly increasing their stakes.
Metagenomi (Nasdaq: MGX) announced it will present new preclinical data involving APOC3 as a collaboration target with Ionis Pharmaceuticals at the Nature Conference in Boston from December 8-10, 2025. The presentation will detail "CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia," delivered by Dr. Alan Brooks. This news, published December 1, 2025, led to an 8.57% decline in MGX stock.
Wilson Sonsini Goodrich & Rosati advised Metagenomi, Inc. on patent matters related to its recent initial public offering. Metagenomi closed its IPO of 6,250,000 shares of common stock at $15.00 per share, raising approximately $93.75 million in gross proceeds. The shares began trading on the Nasdaq Global Select Market under the ticker symbol "MGX."
Metagenomi, a preclinical biotech focused on gene editing therapies, announced terms for its initial public offering, aiming to raise $100 million. The company plans to offer 6.3 million shares at a price range of $15 to $17, which would give it a market value of $600 million at the midpoint. Metagenomi utilizes a proprietary metagenomics-derived genome editing toolbox and plans to list on the Nasdaq under the symbol MGX.
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the 46th Annual TD Cowen Healthcare Conference, being held in Boston, MA, on Monday, March 2, 2026 at 11:10 a.m. E